



## ESOCAP ANNOUNCES PRESENTATION OF NEW DATA AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS' CONGRESS

*Basel, Switzerland, November 6, 2019*

**EsoCap AG announced presentation of new data, with smart application technology in the upper gastrointestinal tract demonstrating that long-lasting topical drug therapy within the esophagus is achievable for the first time.**

The University of Greifswald, Germany, conducted an imaging study in twelve healthy volunteers, with the objective of evaluating esophageal disposition of thin films. The imaging data showed an unrivalled long contact time and good adhesion of the polymer film to the esophageal mucosa.<sup>1,2</sup> The data was presented at the AAPS Congress (American Association of Pharmaceutical Scientists), held on November 3-6, 2019 in San Antonio, Texas.

"This is an extremely exciting time in the field of drug delivery", said Prof. Werner Weitschies, Head of Biopharmaceutics at the Center of Drug Absorption and Transport, University of Greifswald. "Up to now, local treatment of esophageal diseases has been very difficult due to the ultra-short clearance time in the esophagus. The thin film study in healthy volunteers allowed us to visualize consistent disposition of thin films in vivo."

"We are thrilled by the work conducted in Greifswald", said Isabelle Racamier, CEO of EsoCap AG. "The demonstration of successful swallowing by all subjects and effective placement of the thin film on the esophageal mucosa in all cases opens up new therapeutic options for esophageal diseases."

### About EsoCap

EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases through development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times, with less than two seconds from the mouth to the stomach.

EsoCap owns a unique drug delivery platform, allowing the topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.

For more information, please visit [esocapbiotech.com](http://esocapbiotech.com).

### About the University of Greifswald

Across numerous departments and disciplines, the University of Greifswald community advances ideas and innovations that enrich human life. The University's departments encompass a wide range of fields, including General and Clinical Pharmacology, Biopharmaceutics and Pharmaceutical Technology, Pharmaceutical Biotechnology, and all clinical disciplines.

The Center of Drug Absorption and Transport (C\_DAT) is an internationally recognized center of expertise, in which research groups from the University of Greifswald and University Medicine Greifswald investigate the processes of absorption and transport of drugs through to their desired - and unwanted - sites of effect in the human body.

The C\_DAT is respected worldwide, and is a leading center of excellence for drug absorption and transport in Europe.

<sup>1</sup> Grimm, M., Rosenbaum, C., Braun, H., et al. (2019). Characterization of the performance of a novel esophageal drug delivery system in humans. *Poster Presentation, AAPS Annual Meeting 2019*.

<sup>2</sup> Rosenbaum, C., Krause, J., et al. (2019). Development of a novel and innovative drug delivery system for local targeting of the esophagus. *Poster Presentation, AAPS Annual Meeting 2019*.



EsoCap

---

## Contacts:

### **Isabelle Racamier, CEO**

EsoCap AG  
Malzgasse 9  
4052 Basel  
Switzerland

[isabelle.racamier@esocapbiotech.com](mailto:isabelle.racamier@esocapbiotech.com)

### **Prof. Dr. Werner Weitschies**

University of Greifswald  
Center of Drug Absorption and Transport  
Institute of Pharmacy  
Felix-Hausdorff-Strasse 3  
17487 Greifswald  
Germany

[werner.weitschies@uni-greifswald.de](mailto:werner.weitschies@uni-greifswald.de)